Lupus & antiphospholipid syndrome
Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study
Authors' conclusion
Smoking is related to increased arterial events and poor prognosis in TAPS patients.
Study context
- Population
- Patients diagnosed with thrombotic APS (TAPS), 2013 to 202257 vs 57 matched analysed
- Participants
- 297 patients
- Exposure
- Smokers vs non-smokers with thrombotic APS
- Smokersn = 82
- Non-smokersn = 215reference
- Outcome
- Arterial thrombosis (after matching)
Methodological detailspropensity-score matched by age and sex
- Propensity-score matched by age and sex
Main finding
As reported in the abstract
P = 0.005
Observational data: associations, not effects.
Further findings
Arterial thrombotic events at diagnosis (overall cohort)
P = 0.013
Cardiovascular organ damage (matched) · follow-up
P = 0.001
Gastrointestinal organ damage (matched) · follow-up
P = 0.016
Ophthalmologic organ damage (matched) · follow-up
P = 0.027
Hypertension (overall cohort)
P < 0.001
Obesity (overall cohort)
P = 0.029
Dyslipidaemia (overall cohort)
P = 0.012
Hyperhomocysteinaemia (overall cohort)
P < 0.001
Median
| Outcome | Smokers | Non-smokers | P value |
|---|---|---|---|
| Damage Index for APS score (matched) · follow-up | 2.00 | 1.00 | P = 0.008 |
Recurrent thrombosis during follow-up
- Smokers had a tendency for more recurrent arterial and less recurrent venous thrombosis
Original publication
Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study. Rheumatology (Oxford). Published 20 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →